A

Akero Therapeutics
D

AKRO

24.990
USD
-0.60
(-2.34%)
مغلق
حجم التداول
26,531
الربح لكل سهم
-4
العائد الربحي
-
P/E
-7
حجم السوق
1,744,280,709
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
الأخبار
المقالات

العنوان: Akero Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.